Skip to Content

CRISPR Therapeutics AG CRSP

Morningstar Rating
$59.60 −0.97 (1.60%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Positive Outlook for Crispr Therapeutics Thanks to Blockbuster Potential of Casgevy

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company's proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Price vs Fair Value

CRSP is trading at a 19% premium.
Price
$59.60
Fair Value
$924.00
Uncertainty
Very High
1-Star Price
$316.38
5-Star Price
$59.50
Economic Moat
Fgmd
Capital Allocation
Rqmsjsdvb

Bulls Say, Bears Say

Bulls

Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Crispr Therapeutics’ pipeline is largely in the early stages of development and years away from potentially receiving approval.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRSP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$60.57
Day Range
$58.0560.19
52-Week Range
$37.5591.10
Bid/Ask
$59.10 / $60.50
Market Cap
$5.06 Bil
Volume/Avg
1,750 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
17.66
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
407

Competitors

Valuation

Metric
CRSP
VRTX
BNTX
Price/Earnings (Normalized)
27.8427.08
Price/Book Value
2.436.560.95
Price/Sales
17.6612.077.00
Price/Cash Flow
29.13
Price/Earnings
CRSP
VRTX
BNTX

Financial Strength

Metric
CRSP
VRTX
BNTX
Quick Ratio
17.723.1510.95
Current Ratio
17.813.5011.38
Interest Coverage
95.99
Quick Ratio
CRSP
VRTX
BNTX

Profitability

Metric
CRSP
VRTX
BNTX
Return on Assets (Normalized)
−6.45%20.50%−0.14%
Return on Equity (Normalized)
−7.71%26.75%−0.15%
Return on Invested Capital (Normalized)
−6.83%22.49%−2.21%
Return on Assets
CRSP
VRTX
BNTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
HfqqwgfvYxldb$637.8 Bil
Vertex Pharmaceuticals Inc
VRTX
SwlgsmjWtpcpg$121.6 Bil
Regeneron Pharmaceuticals Inc
REGN
CdtggwdvCrpzzgx$115.1 Bil
Moderna Inc
MRNA
BxtplsnhXnmpj$51.5 Bil
argenx SE ADR
ARGX
YmffdcmhFml$22.9 Bil
BioNTech SE ADR
BNTX
CsnmkjrlTcg$20.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
FmkblrkmKbccz$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
PrskgynyNvxrvtc$16.1 Bil
United Therapeutics Corp
UTHR
KpbmnjvjSxlb$13.7 Bil
Incyte Corp
INCY
LxsgplrqRdxwfrt$12.3 Bil

Sponsor Center